Zydus Lifesciences Limited announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2025, reporting robust growth across key financial parameters.

For the second quarter of FY26, the Company recorded revenue from operations of Rs. 6,123.2 crore, reflecting a strong 17 per cent year-on-year increase. Strategic investments in research and development remained a priority, with R&D expenditure amounting to Rs. 482 crore, representing 7.9 per cent of quarterly revenues.

The company delivered a healthy improvement in profitability, as EBITDA rose 38 per cent year-on-year to Rs. 2,015.8 crore. EBITDA margin expanded by 500 basis points over the previous year, reaching 32.9 per cent. Net profit for the quarter also registered a solid 38 per cent growth, standing at Rs. 1,258.6 crore. Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives.

For the first half of FY26, revenue from operations stood at Rs. 12,696.9 crore, an increase of 11 per cent year-on-year. R&D investments for the period were Rs. 967.6 crore, accounting for 7.6 per cent of revenues. EBITDA increased 16 per cent year-on-year to Rs. 4,104.3 crore, with the EBITDA margin improving by 130 basis points to 32.3 per cent. Net profit for the half year stood at Rs. 2,725.4 crore, up 17 per cent year-on-year. Organic capex during the first half totaled Rs. 893.1 crore. The company continued to maintain a strong balance sheet position, with Net Debt to Equity at 0.09x and Net Debt to EBITDA at 0.3x as of September 30, 2025.

The strong performance reflects the Company’s focus on accelerating growth, strengthening its research-led innovation strategy, and delivering value across key markets.